ASTRANA HEALTH, INC.
boothcheck covers ASTRANA HEALTH, INC. (ASTH) but does not put one priced-in number on it: here the defensible answer is the evidence rather than a point estimate. boothcheck publishes no house fair value, target price, or buy/sell rating. Narrative composed July 25, 2026.
• Sixty percent of revenue comes from Medicare and another 27% from Medicaid, so the top line is set by two government payers while the costs are set by how sick the patients turn out to be. • The 2025 accounts show what buying scale looks like before it works: capitation revenue reached $2,840.2 million against $1,763.2 million in 2024, while the Care Delivery segment added $114.1 million of revenue and lost $2.1 million of segment operating income [Source: FY2025 10-K]. • The thing to watch
Is ASTH overvalued? See what's priced in →
163 institutional managers reported holding ASTH in 13F filings for the quarter ended 2026-03-31. Together they hold about 61% of the company; the top 10 hold 40%. 20 opened new positions that quarter. Held by BlackRock, Vanguard Group, State Street, among others. On the short side, 2.4M shares were sold short as of the 2026-06-15 count, about 5% of shares outstanding (4.5 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
ASTH's share count grew 10.6% over the past five years even with $51.50M spent on repurchases. It pays a dividend, and has for 9 years running. Cash returned over the past three years: $73.26M in dividends and $29.95M in repurchases.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
No open-market insider buys on file at ASTH over the trailing three years. Absence is a fact about the company, not a signal. 13 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
ASTH's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-08-10 | +4.0% | -19.7% |
| 2023-11-10 | +9.3% | +21.4% |
| 2024-03-01 | -0.5% | -13.7% |
| 2024-05-10 | -0.9% | +21.4% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
ASTH's latest 8-K filings: 2026-07-13 (items 7.01, 9.01); 2026-07-01 (items 5.02); 2026-06-10 (items 5.02, 5.07, 9.01); 2026-05-12 (items 5.02); 2026-05-12 (items 7.01, 9.01).
Item codes are the SEC's own classification of what each report discloses. Dates link to the filing on EDGAR. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: July 25, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.